Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel

Exclusion Criteria

• •Stage IV metastatic breast cancer
• •Inflammatory breast cancer
• •Previous anti-cancer therapy or radiotherapy for any malignancy
• •History of other malignancy within 5 years prior to screening, except for appropriately-treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer
• •Concurrent anti-cancer treatment in another investigational trial, including hormone therapy, bisphosphonate therapy, or immunotherapy
• •Major surgical procedure unrelated to breast cancer within 4 weeks prior to randomization or from which the participant has not fully recovered
• •Serious cardiac illness or medical condition
• •Other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness
• •Any abnormalities in liver, kidney or hematologic function laboratory tests immediately prior to randomization
• •Sensitivity to any of the study medications, any of the ingredients or excipients of these medications, or benzyl alcohol
• •Pregnant or lactating